What AMIC does that microfracture alone cannot

Knee cartilage damage tends not to heal on its own — cartilage has no direct blood supply, which means even a small, full-thickness defect can slowly worsen without intervention. AMIC (Autologous Matrix-Induced Chondrogenesis) is a single-operation technique designed to repair those defects more durably than standard microfracture surgery alone.

Microfracture has been used for decades as a first-line response to focal cartilage loss. The surgeon perforates the subchondral bone beneath the damaged area, releasing marrow stem cells and growth factors that form a blood clot — a biological scaffold that can mature into repair tissue. The problem is mechanical: that clot is inherently unstable, prone to displacement, and the fibrocartilage it produces tends to degrade over time. Kreuz et al. documented a significant decline in clinical scores between 18 and 36 months after microfracture of the trochlea, patella, or tibia, with survivorship falling below 60% at three years. For many patients, early gains fade before the repair has had a chance to consolidate.

AMIC, first introduced by Behrens et al., was developed specifically to address that durability failure. After completing the microfracture step, the surgeon fixes a resorbable bilayer collagen I/III membrane — Chondro-Gide, manufactured by Geistlich Pharma — over the prepared defect. The membrane holds the marrow clot in place, concentrates the growth factors released from the bone, and guides the mesenchymal progenitor cells toward fibrocartilaginous repair tissue rather than allowing the clot to disperse.

Critically, the entire process happens within a single operation. Techniques such as ACI (Autologous Chondrocyte Implantation) or MACI require a biopsy at one procedure and a second operation weeks later to implant cultured cells. AMIC eliminates that two-stage pathway — one anaesthetic, one recovery, one procedure that both stimulates and stabilises the repair.

Who is a suitable candidate

Surgeons assessing a patient for AMIC are looking for a specific injury pattern — not simply a painful knee. The features below are what a pre-operative consultation will examine.

The lesion itself

AMIC is designed for focal, full-thickness chondral or osteochondral defects — Outerbridge (ICRS) Grade III or Grade IV lesions where cartilage loss extends to or through the subchondral bone. Equally important is what surrounds the defect: the cartilage border (the 'shoulder') should be stable and healthy, and the surrounding joint surface should not show diffuse degenerative change. Patients with widespread or advanced osteoarthritis are generally not suitable; AMIC addresses focal holes in cartilage, not generalised joint-surface loss.

Age and activity level

Although there is no hard age cutoff, AMIC fits best within a joint-preservation cohort — active patients for whom a joint replacement would be premature. The AMIC Registry reflects this: the mean patient age was 37.3 years, a figure that illustrates the typical younger-to-middle-age profile rather than defining an absolute upper limit. Patients somewhat over 60 may still be assessed on individual merit, particularly if the knee is otherwise in good condition.

Knee stability and alignment

A repaired cartilage patch can only consolidate if the mechanical environment around it is sound. Ligamentous instability or malalignment overloads the repair tissue and significantly reduces its chances of surviving. Where either is present, surgical correction — ligament reconstruction or an osteotomy to realign the limb — may need to happen before or at the same time as the AMIC procedure. Patients are sometimes surprised that a separate corrective step might be necessary; the pre-operative assessment is where this is determined.

Prior procedures and general health factors

Previous marrow-stimulation surgery (microfracture) can damage the subchondral bone plate and may affect the quality of the repair bed; this is one reason why the history of prior interventions is discussed at assessment. BMI and smoking status also influence tissue healing and are relevant considerations, though they are factors to weigh rather than automatic disqualifiers.

The role of MRI

MRI is the standard first diagnostic step because X-ray and CT cannot reliably map defect depth, subchondral bone status, or the condition of the surrounding cartilage. At Lincolnshire Knee, the pre-operative work-up typically combines MRI with biomechanical assessment — objective data on load distribution and alignment — to build a complete picture before any procedure is planned.

Defect size: where AMIC fits in the repair spectrum

Defect area is the single most important variable in choosing between cartilage repair options, and it is measured on MRI before the procedure then confirmed intraoperatively once the damaged tissue is debrided.

Below approximately 2 cm²

For smaller focal defects, microfracture alone or osteochondral autograft transfer (OATS / mosaicplasty) are reasonable first choices. At this scale, the biological case for adding a collagen membrane is less clear-cut and is unlikely to be cost-justified in most clinical settings.

The AMIC range: roughly 2–10 cm²

Once a defect exceeds around 2 cm², the durability argument for membrane augmentation strengthens considerably. Schiavone Panni et al. demonstrated sustained benefit in patients with full-thickness defects larger than 2 cm² at seven-year follow-up. The AMIC Registry (Gille et al., 57 patients) recorded a mean treated defect of 3.4 cm² — range 1.0–12.0 cm² — reflecting the breadth of this middle tier in clinical practice.

Within this range, AMIC offers a practical single-stage alternative to two-stage cell-based therapies. Fossum et al. conducted a prospective RCT comparing AMIC directly with collagen-membrane ACI (ACI-C) for distal femur and patella defects and found comparable clinical outcomes between the two techniques. The sample was small (41 patients), so this result is best read as evidence of non-inferiority rather than proof of equivalence at scale.

Larger defects: above roughly 10 cm²

At the far end of the spectrum — very large posttraumatic lesions or those involving significant osteochondral loss — fresh osteochondral allograft (OCA) or a full cell-based pathway such as MACI or ACI is more likely to be appropriate. The SUMMIT trial established that defects of 3 cm² or more respond better to scaffold or cell-based augmentation than to microfracture alone, and for the largest lesions, autograft supply becomes a limiting factor that shifts the balance toward allograft options.

The procedure and what recovery involves

For most patients, AMIC is performed under a single general or spinal anaesthetic and is completed in one sitting — no cell-harvesting appointment, no second operation.

What happens in the operating theatre

The surgeon approaches the knee either through a small open incision (mini-open) or using a camera and keyhole ports (arthroscopic); the choice depends on where the defect sits and the surgeon's preferred technique. Once the defect is exposed, four steps follow in sequence:

• Unstable and damaged cartilage is removed with a scalpel and curette until healthy, vertical cartilage borders surround the lesion.
• A sterile aluminium template is pressed into the defect to capture its exact shape, then transferred to the Chondro-Gide collagen membrane, which is cut to fit.
• The subchondral bone is perforated (microfracture) to release marrow blood and progenitor cells, forming a super clot within the defect.
• The membrane is fixed over the clot using suture or fibrin glue, protecting it and guiding the incoming cells toward fibrocartilaginous repair tissue.

Most patients are discharged the same day or after one overnight stay.

Recovery and rehabilitation

The repair tissue is fragile in the early weeks. Protected weight-bearing — crutches, limited load — is usually required for the first four to six weeks, followed by a phased return to normal movement under physiotherapy guidance. Cartilage-like repair tissue continues to mature for up to 9–18 months after surgery; returning to full activity before that window closes risks damaging tissue that has not yet consolidated.

MRI follow-up and known complications

A follow-up MRI scan is typically used to assess how well the defect has filled with repair tissue. In some cases the repair tissue becomes thickened (hypertrophy), and subchondral bone cyst formation beneath the repair site has been observed in research settings — a finding from animal studies by Beck et al. (2016) that clinicians continue to monitor in longer-term follow-up. Neither complication is universal, but both are reasons why ongoing review rather than a single discharge appointment is appropriate after AMIC.

What the clinical evidence shows

Published outcome data give patients a reasonable basis for calibrated confidence — not certainty, but an evidence-backed expectation of meaningful improvement.

The AMIC Registry (Gille et al., 57 patients; mean age 37.3 years; mean defect 3.4 cm²) recorded a statistically significant reduction in pain on the visual analogue scale (VAS; p<0.001) alongside measurable gains in knee function at both one and two years post-surgery. The Volz et al. five-year RCT (2017) extended this picture, confirming that both pain reduction and functional improvement were sustained over a five-year horizon when compared with microfracture alone — directly addressing the durability concern that limits standard microfracture's long-term value.

Where the evidence is thinner, honesty is appropriate. No large post-5-year registry has yet reported on AMIC outcomes. The Fossum RCT, which found AMIC broadly comparable to collagen-membrane ACI for distal femur and patella defects, enrolled only 41 patients — sufficient to suggest non-inferiority, but not a definitive verdict at scale. Long-term superiority over microfracture is biologically plausible, given the membrane's role in stabilising repair tissue, but has not yet been confirmed in a large powered trial.

Subchondral bone changes beneath the repair site — noted in the published literature and flagged in s4 — remain a recognised monitoring concern, which is why follow-up imaging after AMIC is standard practice rather than optional.

Getting assessed for AMIC in Lincolnshire

AMIC is not currently funded through NHS pathways in Lincolnshire, and access to the procedure in the region is through private orthopaedic services.

Lincolnshire Knee, part of the MSK Doctors group, offers consultant-led assessment at clinics in Sleaford (NG34) and Grantham (NG31) — no GP referral is required, and there is no NHS-style waiting list. The initial assessment brings together MRI with cartilage-specific sequences, which characterise defect depth, area, and subchondral bone status, alongside a biomechanical evaluation of how load is distributed across the joint. Where clinically appropriate, onMRI™ AI-driven cartilage analysis and MAI Motion® objective gait assessment contribute to that picture. A consultant then reviews the imaging, confirms defect grading and sizing, and determines whether AMIC, an alternative restorative technique, or a staged approach best fits the individual knee.

The evidence reviewed in this article consistently shows that outcomes are meaningfully better when patients are selected carefully and treated before degeneration spreads beyond a focal lesion — the assessment step is where that opportunity is either captured or lost. Book an assessment at lincolnshireknee.co.uk.